Compare FUBO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | ARMP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.4M | 295.5M |
| IPO Year | 2011 | 1996 |
| Metric | FUBO | ARMP |
|---|---|---|
| Price | $10.20 | $5.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $20.33 | $15.00 |
| AVG Volume (30 Days) | ★ 1.5M | 173.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,271,000.00 | N/A |
| Revenue This Year | $44.64 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10317.07 | N/A |
| 52 Week Low | $1.02 | $2.14 |
| 52 Week High | $14.54 | $14.98 |
| Indicator | FUBO | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 35.27 |
| Support Level | $9.13 | $5.14 |
| Resistance Level | $10.76 | $7.93 |
| Average True Range (ATR) | 0.78 | 0.72 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 85.88 | 8.50 |
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. It operates in a single segment of the streaming business.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.